Pancreatic Cancer Research

ResearcherAsan Medical CenterNo recent work listed

Myung‐Hwan Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0992-6734; OpenAlex author ID A5017869417. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 4 papers

Papers 17

  1. Systematic review and meta-analysis of MRI features for differentiating autoimmune pancreatitis from pancreatic adenocarcinoma. Last author DOI 10.1007/s00330-022-08816-1↗
  2. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Last author DOI 10.1007/s00464-021-08627-3↗
  3. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  4. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Last author DOI 10.4103/eus-d-21-00049↗
  5. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  6. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  7. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  8. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  9. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-018-5565-1↗
  10. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  11. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  12. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Last author DOI 10.5009/gnl17391↗
  13. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. Last author DOI 10.1259/bjr.20160403↗
  14. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  15. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Last author DOI 10.1016/j.gie.2015.08.048↗
  16. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗
  17. Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? First author DOI 10.1097/mpa.0b013e31823a509b↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Do Hyun Park · 14 shared papers, 2012–2022 · strength 1.16
  2. Tae Jun Song · 12 shared papers, 2016–2022 · strength 1.10
  3. Sang Soo Lee · 12 shared papers, 2012–2022 · strength 0.94
  4. Dong Wan Seo · 10 shared papers, 2012–2022 · strength 0.73
  5. Dongwook Oh · 6 shared papers, 2016–2022 · strength 0.67
  6. Song Cheol Kim · 9 shared papers, 2012–2022 · strength 0.67
  7. Kyu‐pyo Kim · 8 shared papers, 2017–2022 · strength 0.64
  8. Baek‐Yeol Ryoo · 8 shared papers, 2017–2022 · strength 0.64
  9. Changhoon Yoo · 8 shared papers, 2017–2022 · strength 0.64
  10. Ki Byung Song · 7 shared papers, 2017–2022 · strength 0.56
  11. Dae Wook Hwang · 7 shared papers, 2017–2022 · strength 0.56
  12. Jin‐hong Park · 7 shared papers, 2012–2022 · strength 0.54
  13. Sung‐Hoon Moon · 3 shared papers, 2012–2022 · strength 0.31
  14. Dong‐Wan Seo · 2 shared papers, 2022 · strength 0.31
  15. Inhwan Hwang · 3 shared papers, 2018–2020 · strength 0.24
  16. Sang Hyun Shin · 4 shared papers, 2012–2019 · strength 0.23
  17. Jae Ho Byun · 3 shared papers, 2012–2020 · strength 0.20
  18. Tae Yeon Jeon · 1 shared paper, 2022 · strength 0.20
  19. Sang Min Lee · 1 shared paper, 2022 · strength 0.20
  20. Seung Bae Yoon · 1 shared paper, 2022 · strength 0.20
  21. Jin Hee Kim · 3 shared papers, 2012–2020 · strength 0.20
  22. Seung Soo Lee · 3 shared papers, 2012–2020 · strength 0.20
  23. Woohyung Lee · 2 shared papers, 2020 · strength 0.17
  24. Hyoung Jung Kim · 2 shared papers, 2017–2018 · strength 0.16
  25. Kyoungmin Lee · 2 shared papers, 2018–2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.